Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PER-047-00
PER-047-00Completed未知

OPEN MULTICENTRIC CLINICAL STUDY TO EVALUATE THE LONG-TERM SECURITY IN 4 MG OF ZOMETA (ZOLEDRONATE) IN PATIENTS WITH METASTASIC BONE INJURIES FROM BREAST CANCER OR MULTIPLE MYELOMA

OVARTIS BIOSCIENSES PERU S.A.,0 sites0 target enrollmentStarted: August 8, 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Signed informed consent
  • •Patients who have completed the 6 cycles of treatment with Aredia® or Zometa® from the central study
  • •Performance status O, I, II (WHO Classification)
  • •Normal corrected serum calcium level or mild hypercalcemia

Exclusion Criteria

  • •Patients with abnormal renal function evidenced either by a serum creatinine determination 1.5 times or more above the normal upper limit or by a calculated creatinine clearance of 60 mL / minute or less.
  • •Pregnancy and lactation
  • •Women of potential pregnancy age who are not under some medically recognized method of contraception
  • •Persons who, in the investigator´s judgment, are unlikely to cooperate fully during the study
  • •People who are participating simultaneously in studies with drugs, indications or non-approved treatment regimens. People who are participating in studies with approved drugs in approved indications are allowed using approved treatment regimens.

Investigators

Sponsor
OVARTIS BIOSCIENSES PERU S.A.,

Similar Trials

Active, not recruiting
Phase 1
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency
EUCTR2018-003163-67-PTAeglea Biotherapeutics, Inc.14
Active, not recruiting
Phase 1
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyArginase 1 deficiency HyperargininemiaMedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2018-003163-67-GBAeglea Biotherapeutics, Inc.14
Active, not recruiting
Not Applicable
An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder - Lamda extensioAttention Deficit-Hyperactivity Disorder (ADHD)MedDRA version: 7.1Level: LLTClassification code 10003735
EUCTR2005-004037-18-ESJanssen-Cilag Medical Affairs EMEA250
Active, not recruiting
Not Applicable
An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder - Lamda extensio
EUCTR2005-004037-18-DEJanssen-Cilag Medical Affairs EMEA160
Active, not recruiting
Phase 1
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
EUCTR2015-004110-23-FIGrifols Therapeutics LLC250